Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)

Philip Morris

Status: Completed

Conditions: Smoking

Treatments: Other: NNS; Other: THS 2.2; Other: CC

Study type: Interventional

Funder types: Industry

Identifiers

NCT01967732

2013-003097-27 (EudraCT Number)

ZRHR-PK-01-EU (Other Identifier)

Details and patient eligibility

About

The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile (rate and amount of nicotine absorbed) following a single use of the THS 2.2 compared to the PK profiles from a single use of a conventional cigarette (CC) and from a single use of nicotine nasal spray (NNS).

Enrollment: 62 patients

Sex: All

Ages: 21 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subject is Caucasian
• Smoking, healthy subject as judged by the Investigator.
• Subject has smoked at least 10 commercially available non menthol CCs per day (no brand restrictions) for the last 4 weeks.
• Subject has smoked for at least the last 3 consecutive years.
• Subject does not plan to quit smoking in the next 3 months.

Exclusion criteria

• As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason).
• Subject has received medication within 14 days or within 5 half-lives of a drug (whichever is longer) which has an impact on CYP2A6 activity.
• Female subject is pregnant or breast feeding.
• Female subject does not agree to use an acceptable method of effective contraception.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

62 participants in 4 patient groups

THS 2.2 then CC

Active Comparator group

Description:

Each subject will follow the below study design: * Day 0 = Wash-out (1 day) * Day 1 = 1st intervention (single product use of THS 2.2) * Day 2 = wash-out * Day 3 = 2nd intervention (single product use of CC).

Treatment:

Other: THS 2.2

Other: CC

CC then THS 2.2

Active Comparator group

Description:

Each subject will follow the below study design: * Day 0 = Wash-out (1 day) * Day 1 = 1st intervention (single product use of CC) * Day 2 = wash-out * Day 3 = 2nd intervention (single product use of THS 2.2).

Treatment:

Other: THS 2.2

Other: CC

THS 2.2 then NNS

Active Comparator group

Description:

Each subject will follow the below study design: * Day 0 = Wash-out (1 day) * Day 1 = 1st intervention (single product use of THS 2.2) * Day 2 = wash-out * Day 3 = 2nd intervention (single administration of NNS)

Treatment:

Other: NNS

Other: THS 2.2

NNS then THS 2.2

Active Comparator group

Description:

Each subject will follow the below study design: * Day 0 = Wash-out (1 day) * Day 1 = 1st intervention (single administration of NNS) * Day 2 = wash-out * Day 3 = 2nd intervention (single product use of THS 2.2).

Treatment:

Other: NNS

Other: THS 2.2